GlycoMar Limited is a privately held marine biotechnology company dedicated to the discovery, development and commercialisation of new anti-inflammatory drug candidates based on the glycobiology of marine organisms. The Company was established in February 2005 with seed funding from the founder, one corporate investor, and business angels.
Fundamentally, as part of its rapid growth business strategy, the Company concentrates on identifying compounds that have a short lead in time to market, combined with a high return ratio on R & D. As proof of this GlycoMar is already supplying a group of polysaccharide and glycoprotein products to two drug development companies. Over the next 12 months GlycoMar is targeting an increase in sales to over £200,000 per annum. The Company has recently introduced a commercial screening service having secured contracts with drug discovery companies. Within the next 12 months, based on commercial success, it aims to raise a further £2.5 million in investment in order to expand and accelerate its drug discovery operations, taking lead compounds into clinical development.
